0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
The Best of the Best |

Top-Accessed Article: Severe Hidradenitis Suppurativa Treated With Infliximab Infusion FREE

Iltefat H. Hamzavi, MD
Arch Dermatol. 2012;148(7):802. doi:10.1001/archdermatol.2012.542.
Text Size: A A A
Published online

Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003;139(12):1540-1542.

Hidradenitis suppurativa (HS) remains one of the most challenging and humiliating diseases in dermatology. It occurs in 1% to 2% of the population and is categorized into 3 stages. The third stage has very few treatment options, and the most successful to date has been infliximab.1 Since the article by Adams and colleagues, there have been 8 studies looking at the use of infliximab for HS. One of the few double-blind placebo-controlled studies published for any treatment option for HS showed a 50% improvement compared with placebo.2 In my experience, inflixmab infusion is not a cure, but it does offer significant improvement in pain, swelling, and drainage. It also may offer insight into the mechanism of this disabling condition.

From October 2010 to August 2011, this article was accessed 2367 times on the Archives of Dermatology Web site.

ARTICLE INFORMATION

Contact Dr Hamzavi at the Department of Dermatology, Center for Multicultural Dermatology, Henry Ford Hospital, 3031 W Grand Blvd, Ste 800, Detroit, MI 48202 (ihamzav1@hfhs.org).

Rambhatla PV, Lim HW, Hamzavi I. A systematic review of treatments for hidradenitis suppurativa [published ahead of print December 19, 2011].  Arch Dermatol
PubMed  |  Link to Article
Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial.  J Am Acad Dermatol. 2010;62(2):205-217
PubMed   |  Link to Article

Figures

Tables

References

Rambhatla PV, Lim HW, Hamzavi I. A systematic review of treatments for hidradenitis suppurativa [published ahead of print December 19, 2011].  Arch Dermatol
PubMed  |  Link to Article
Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial.  J Am Acad Dermatol. 2010;62(2):205-217
PubMed   |  Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.